Total costs | Age at baseline (every 5-year increase) | 1.06 (1.02 to 1.11) | 0.006 | 0.060 | 0.022 | 0.017 | 0.102 | 0.055 | 0.065 | 1.06 | 1.07 |
Male vs female | 0.75 (0.65 to 0.87) | 0.000 | −0.287 | 0.074 | −0.432 | −0.142 | −0.304 | −0.265 | 0.74 | 0.77 |
Time on biologics (in months) | 1.23 (1.21 to 1.24) | <0.0001 | 0.205 | 0.005 | 0.195 | 0.216 | 0.205 | 0.205 | 1.23 | 1.23 |
Year 2 vs year 1 | 0.89 (0.78 to 1.01) | 0.063 | −0.119 | 0.064 | −0.244 | 0.007 | −0.125 | −0.114 | 0.88 | 0.89 |
Year 3 vs year 1 | 0.71 (0.63 to 0.81) | <0.0001 | −0.339 | 0.062 | −0.462 | −0.217 | −0.367 | −0.321 | 0.69 | 0.73 |
Average BASFI score (every 10-point increase) | 1.18 (1.15 to 1.22) | <0.0001 | 0.168 | 0.015 | 0.137 | 0.198 | 0.164 | 0.172 | 1.18 | 1.19 |
Presence of peripheral arthritis at baseline | 1.19 (1.04 to 1.37) | 0.014 | 0.177 | 0.072 | 0.036 | 0.318 | 0.166 | 0.198 | 1.18 | 1.22 |
Non-biologic costs | Age at baseline (every 5-year increase) | 1.10 (1.05 to 1.16) | 0.000 | 0.097 | 0.025 | 0.047 | 0.147 | 0.092 | 0.104 | 1.10 | 1.11 |
Male vs female | 0.69 (0.58 to 0.81) | <0.0001 | −0.377 | 0.087 | −0.548 | −0.206 | −0.398 | −0.349 | 0.67 | 0.71 |
Time on biologics (in months) | 1.04 (1.02 to 1.05) | <0.0001 | 0.037 | 0.008 | 0.022 | 0.052 | 0.037 | 0.038 | 1.04 | 1.04 |
Year 2 vs year 1 | 0.87 (0.75 to 1.00) | 0.050 | −0.143 | 0.073 | −0.286 | 0.000 | −0.151 | −0.139 | 0.86 | 0.87 |
Year 3 vs year 1 | 0.72 (0.63 to 0.83) | <0.0001 | −0.327 | 0.072 | −0.470 | −0.184 | −0.357 | −0.301 | 0.70 | 0.74 |
Average BASDAI score (every 10-point increase) | 1.21 (1.16 to 1.25) | <0.0001 | 0.187 | 0.019 | 0.151 | 0.224 | 0.185 | 0.192 | 1.20 | 1.21 |
Presence of peripheral arthritis at baseline | 1.20 (1.02 to 1.40) | 0.024 | 0.181 | 0.080 | 0.024 | 0.338 | 0.170 | 0.198 | 1.18 | 1.22 |